US FDA advisers back Novo Nordisk genetic insulins, despite worries
This article was originally published in Scrip
Executive Summary
Novo Nordisk’s bid to get marketing approval from the US FDA for the company’s new long-lasting insulin got a lukewarm endorsement on 8 November from the agency’s panel of outside experts.